贝达药业
(300558)
| 流通市值：236.46亿 | | | 总市值：237.20亿 |
| 流通股本：4.17亿 | | | 总股本：4.18亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,344,643,009.24 | 1,500,765,619.93 | 735,775,468.8 | 2,456,196,486.62 |
| 营业收入 | 2,344,643,009.24 | 1,500,765,619.93 | 735,775,468.8 | 2,456,196,486.62 |
| 二、营业总成本 | 1,978,236,019.16 | 1,261,367,094.02 | 641,561,760.14 | 2,213,916,621.77 |
| 营业成本 | 379,678,886.5 | 242,268,006.57 | 128,543,650.38 | 404,482,752.66 |
| 税金及附加 | 14,981,333.66 | 9,856,528.35 | 5,111,271.91 | 14,066,610.05 |
| 销售费用 | 870,560,375.36 | 523,705,958.87 | 230,482,714.67 | 853,886,240.4 |
| 管理费用 | 294,428,944.09 | 211,128,410.02 | 114,726,159.34 | 261,755,974.75 |
| 研发费用 | 384,037,587.9 | 256,279,592.48 | 152,750,433.4 | 640,138,657.34 |
| 财务费用 | 34,548,891.65 | 18,128,597.73 | 9,947,530.44 | 39,586,386.57 |
| 其中:利息费用 | 31,546,113.12 | 22,276,864.69 | 11,007,909.82 | 54,954,618.01 |
| 其中:利息收入 | 5,131,459.03 | 3,960,073.02 | 2,640,174.93 | 10,234,964.82 |
| 加:公允价值变动收益 | 46,809,685.04 | - | - | -312,610.4 |
| 加:投资收益 | -6,506,775.59 | -5,183,673.02 | -2,152,030 | -13,357,149.44 |
| 资产处置收益 | 121,274.35 | -6,188,472.88 | -1,771,123.17 | -10,730.91 |
| 信用减值损失(新) | 6,830,096.41 | 6,820,484.35 | 5,073,974.72 | -8,800,936.94 |
| 其他收益 | 24,610,543.77 | 19,044,233.23 | 12,995,099.04 | 50,271,066.63 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 438,271,814.06 | 253,891,097.59 | 108,359,629.25 | 270,069,503.79 |
| 加:营业外收入 | 211,665.43 | 215,266.85 | - | 61,581,462.69 |
| 减:营业外支出 | 6,659,971.9 | 4,023,648.35 | 1,132,320.36 | 9,576,402.29 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 431,823,507.59 | 250,082,716.09 | 107,227,308.89 | 322,074,564.19 |
| 减:所得税费用 | 26,669,663.57 | 33,958,865.34 | 13,436,506.36 | -11,541,140 |
| 六、净利润 | 405,153,844.02 | 216,123,850.75 | 93,790,802.53 | 333,615,704.19 |
| 持续经营净利润 | 405,153,844.02 | 216,123,850.75 | 93,790,802.53 | 333,615,704.19 |
| 归属于母公司股东的净利润 | 416,225,901.42 | 223,947,809.09 | 98,140,741.56 | 348,032,472.42 |
| 少数股东损益 | -11,072,057.4 | -7,823,958.34 | -4,349,939.03 | -14,416,768.23 |
| (一)基本每股收益 | 0.99 | 0.54 | 0.23 | 0.83 |
| (二)稀释每股收益 | 0.99 | 0.54 | 0.23 | 0.83 |
| 八、其他综合收益 | -32,146,129.61 | 14,552,762.64 | 147,493,168.22 | 60,755,488.95 |
| 归属于母公司股东的其他综合收益 | -32,146,129.61 | 14,552,762.64 | 147,493,168.22 | 60,755,488.95 |
| 九、综合收益总额 | 373,007,714.41 | 230,676,613.39 | 241,283,970.75 | 394,371,193.14 |
| 归属于母公司股东的综合收益总额 | 384,079,771.81 | 238,500,571.73 | 245,633,909.78 | 408,787,961.37 |
| 归属于少数股东的综合收益总额 | -11,072,057.4 | -7,823,958.34 | -4,349,939.03 | -14,416,768.23 |
| 公告日期 | 2024-10-29 | 2024-08-06 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |